Report ID :10161347 |
Published Date : 21 Oct 2022 |
Report Format : |
Delivery Timeline :48-72 Business Hours
"The global acute myeloid leukemia (AML) market is projected to grow lucratively worldwide owing to the increasing incidence and recurrence of acute myeloid leukemia (AML). The growing demand for advanced therapies is also a significant factor in this market. The market is likely to mark the revenue of ~USD 3 billion by 2030, expected to expand at a CAGR of ~13% over the period 2022-2030.
The high prevalence of acute myeloid leukemia treatment is due to factors such as genetic mutations, an unhealthy lifestyle, constant exposure to harmful chemicals such as benzene, and radiation exposure. Furthermore, aging and increasing health needs are expected to drive the market growth.
The current limitations of drug treatment for acute myeloid leukemia will lead to the need for better and more effective therapies, further boosting the market. Limitations include uncontrolled recurrence of these drugs and side effects such as nausea, loss of appetite, and tissue damage.
Therefore, these new drug therapies include midostaurin, CPX-351, quizartinib, treosulfan and estimex. Furthermore, by increasing serine-threonine protein kinase and advancing stem cell transplantation methods, it is expected to increase in the presence of several developed drugs such as marquivo, glasspar, inotuzumab and ozogamicin. As the leukemia market grows, new therapies are anticipated, including farnesyltransferase inhibitors, immunotoxins, alkylating agents, monoclonal antibodies, tyrosine kinase 3 inhibitors such as FMS, and multidrug resistance modulators. Benefits of these treatments include long-term survival, better immunity, and a better quality of life. In addition, early diagnosis of leukemia cells, targeted therapy, and low-risk progression of acute myeloid leukemia recurrence should be predicted.
Then chemotherapy is resumed. Drugs in the pipeline include metabolic inhibitors such as bosutinib, vidaza, bosaloxin, omapro, quizartinib, dacogen, and FLT3 inhibitors. In this field, FLT3 inhibitors are expected to grow faster over the next seven years with the development of targeted therapeutics to treat gene mutations and improve the therapeutic environment. Chemotherapy includes Cytarabine, Claire, Gleevec, Spresel, Frodara, Oncasper, Nelarabine, and Trenda. Chemotherapy is divided into AVD, DC, VCD, FC, hyper-CVAD and FCR. Since 2014, AVD therapy has dominated the AML market due to the lack of more effective treatment regimens and the absence of new targeted therapies. Chemotherapy includes Cytarabine, Claire, Gleevec, Splexel, Frodara, Oncasper, Nelarabine, and Trenda. Cytarabine contributed significantly to high survival rates and other limited treatment options in 2014. It is also expected to have advantages such as improved tolerability and the possibility of combination with other drugs.
Geographically, the acute myeloid leukemia treatment market is segmented into North America, Europe, Asia Pacific, Latin America, Middle East and Africa. In 2021, North America gained a significant market share due to key growth factors such as increasing incidence of acute myeloid leukemia and increasing geriatric population.
In addition, the market in the region is growing due to high-tech health infrastructure, large investments in targeted therapies, drug development, and growing public awareness demands. Asia Pacific is expected to be the fastest growing region during the forecast period owing to growth factors such as increasing investment, increasing disposable income, cancer awareness and growing health infrastructure. better health. Additionally, the growing demand for treatments such as targeted therapies to reduce collateral damage and increase efficacy is expected to drive market demand in the region. Market leaders include Ambit Biosciences Corporation, Genzyme Corporation, Celgene Corporation, Clavis Pharma ASA and Sunsys Pharmaceuticals Inc. and Cephalon Inc.
Bristol Myers Squibb, Novartis International AG, and GlaxoSmithKline. These companies are focusing on new pharmaceutical pipelines, contracts and partnerships. They are also focusing on intensive clinical trials, large investments in research and development, and geographic targeting to gain a larger market share. These companies also seek to increase their market share by improving overall quality and patient care."
Why Choose Kenneth Research ?
-
Insight with Impact : We don’t just gather data — we uncover stories, trends, and opportunities that fuel business growth.
-
Experts Who Get It : Our team speaks your industry’s language and knows what really matters to your customers and market.
-
Custom-Built for You : Forget one-size-fits-all. We craft research and consulting solutions as unique as your business vision.
-
Partners, Not Just Providers : We work with you, not for you — collaborating closely to turn insights into smart, strategic moves.
-
Results That Speak : Our work powers brands, startups, and industry leaders alike — with a track record of ideas that work in the real world.
